Neuraltus ALS Drug Wins Fast Track Orphan Status

Fast track orphan designation of NP-001 for ALS is expected to accelerate approval of Neuraltus’ drug should it be found efficacious in its ongoing Phase II ALS study. NP-001 is believed to combat the neuro-inflammation accompanying disease progression by regulating macrophage activity.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail